Dr. Ari Nowacek is a Partner with ARCH Venture Partners, joining the company as an Analyst in March 2015. Dr. Nowacek focuses on identifying and evaluating new life sciences technologies and provides operating assistance to early-stage portfolio companies. Dr. Nowacek is a co-founder of City Therapeutics, where he currently serves as Senior Vice President of Corporate Development. He was instrumental in the development of several ARCH companies, including Synchon, Basking Bio, HiberCell, Arbor Biotechnologies, and Walden Biosciences, among others.
Dr. Nowacek is a physician-scientist by training with publications in the areas of neuroscience, virology, and antiretroviral therapeutic development. He holds a B.S. in Biology and a B.S. in Psychology from the University of Indiana-Bloomington. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an M.B.A. from the University of Nebraska-Omaha. He subsequently completed a medical residency in pathology and post-doctoral research at The University of Chicago and Massachusetts General Hospital.